MRI-based thrombolytic therapy in acute stroke: Finally, the proof of concept by DEFUSE

Nature Clinical Practice Neurology

Volumn 3, Issue 7, 2007, Pages 370-371

  Köhrmann, Martin ^a   Schellinger, Peter D ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; BRAIN HEMORRHAGE; BRAIN PERFUSION; BRAIN REGION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DRUG EFFICACY; DRUG SAFETY; FATALITY; FIBRINOLYTIC THERAPY; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SHORT SURVEY;

EID: 34447270719     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0529     Document Type: Short Survey

References (5)

1. Köhrmann M et al. (2006) MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: A cohort study. Lancet Neurol 5: 661-667
2. Thomalla G et al. (2006) Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: Comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 37 852-858
3. Hacke W et al. (2005) The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36: 66-73
4. Furlan AJ et al. (2006) Dose Escalation of Desmateplase for Acute Ischemic Stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 37: 1227-1231
5. Albers GW et al. (2006) Results of the Diffusion-Weighted Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. Stroke 37: 635-636